Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
Clene Inc. (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. have reported significant progress in their clinical programs, particularly focusing on the development of CNM-Au8® for treating amyotrophic lateral sclerosis (ALS). The company is advancing toward submitting a New Drug Application (NDA) for this investigational therapy, with expectations set for the fourth quarter of 2025. This development represents a critical milestone in the treatment of neurodegenerative diseases, specifically targeting ALS, which currently has limited therapeutic options.
CEO Rob Etherington emphasized the company's upcoming engagement with the FDA, stating that meetings and biomarker analyses are the final steps before potential NDA submission under the accelerated approval pathway. The extensive survival data generated by CNM-Au8® in ALS patients will be a focal point of these discussions. For more details on the company's progress, visit https://ibn.fm/u9ulP.
CNM-Au8® is a first-in-class therapy designed to improve mitochondrial health and protect neuronal function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress. This mechanism aims to enhance the survival and function of central nervous system cells, offering a novel approach to treating ALS, Parkinson's disease, and multiple sclerosis. The therapy's potential accelerated approval could significantly impact patient care by providing a new treatment option where few exist.
The implications of this advancement are substantial for the ALS community, which has long awaited effective therapies. If approved, CNM-Au8® could improve quality of life and survival outcomes for patients suffering from this debilitating condition. The company's commitment to developing impactful therapeutic agents underscores the importance of continued innovation in neurodegenerative disease treatment. Additional information about Clene Inc. and its programs can be found at https://ibn.fm/CLNN.